DermatologyNews.net

Dermatology Xagena

Xagena Mappa
Medical Meeting
Pneumobase.it
Mediexplorer.it

Ixekizumab ( Taltz ) met the primary and all major secondary endpoints up to week 12 in the phase 4 IXORA-R study, which evaluated the efficacy and safety of Ixekizumab versus Guselkumab ( Tremfya ) i ...


Dupilumab ( Dupixent ) is the first biologic available to treat atopic dermatitis. Its effectiveness and safety were demonstrated in clinical trials. The aim of study was to assess the effectivenes ...


In the U.S.A., an Investigator's Global Assessment ( IGA ) score of less than or equal to 1 ( clear or almost clear skin ) has been the standard measure in regulatory outcomes for registration clinica ...


Epidermal growth factor receptor inhibitors ( EGFRi ), EGFR tyrosine kinase inhibitors ( TKI ) and anti‐EGFR antibodies commonly develop skin toxicities including acneiform eruption. However, precise ...


ECLIPSE trial has demonstrated that Guselkumab ( Tremfya ) was superior to Secukinumab ( Cosentyx ) in treating adults with moderate to severe plaque psoriasis for the primary endpoint assessed at wee ...


Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, is approved for the treatment of moderate-to-severe psoriasis. An overview has analyzed the efficacy o ...


Nail psoriasis is associated with functional impairment, pain and reduced quality of life. The aim of a study was to demonstrate the superiority of Secukinumab ( Cosentyx ) versus placebo in cleari ...


Photodynamic therapy ( PDT ) is an attractive therapy for nonmelanoma skin cancers and actinic keratoses ( AKs ). Daylight-mediated photodynamic therapy is a simple and tolerable treatment procedure ...


Hidradenoma usually presents as a solitary, slow-growing, and solid or cystic nodular lesion, which arises in various anatomical sites. Its diagnosis is occasionally difficult because the tumor shares ...


Bristol-Myers Squibb pioneered the use of immune checkpoint inhibitors for the adjuvant treatment of melanoma, beginning with Yervoy. Five-year overall survival data from the phase 3 CA184-029 trial ...


The results from the one-year phase 3 CHRONOS study have shown that patients receiving the investigational drug Dupilumab ( Dupixent ) with topical corticosteroids ( TCS ) achieved significantly impro ...


Alopecia areata is an autoimmune disease characterized by hair loss mediated by CD8+ T cells. There are no reliably effective therapies for alopecia areat . Based on recent developments in the underst ...


Women represent nearly 8 out of every 10 people with autoimmune diseases. Although the hugely disproportionate statistics are well known, the scientific community is still trying to figure out why wom ...


Findings of a phase 3 study of patients with moderate to severe psoriasis demonstrating that nearly half of adult patients treated with Adalimumab ( Humira ) has achieved at least a 75% improvement in ...


The New England Journal of Medicine ( NEJM ) has published detailed results from three pivotal phase 3 studies, UNCOVER-1, UNCOVER-2 and UNCOVER-3, that have demonstrated the efficacy and safety of Ix ...